Atara Biotherapeutics (ATRA) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Atara Biotherapeutics (ATRA) over the past year, losing 30.5% versus a loss of 40.1%. Atara Biotherapeutics is the larger company by market cap ($94.1 million vs $74.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | OKYO |
|---|---|---|
| Share price | $9.37 | $1.41 |
| Market cap | $94.05M | $74.00M |
| 1-day change | -3.90% | -3.42% |
| YTD return | -48.20% | -31.88% |
| 1-year return | -40.05% | -30.54% |
| 5-year return | -97.52% | — |
| Forward P/E | 6.06 | — |
| EPS (TTM) | $-1.30 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.15 | $3.20 |
| 52-week low | $3.92 | $1.27 |
| Distance from 52-week high | -51.06% | -55.94% |
| Average volume | 54.79K | 104.86K |
| Shares outstanding | 10.04M | 52.48M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ATRA vs OKYO FAQ
Which is bigger, Atara Biotherapeutics or OKYO Pharma?
Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $94.05M compared with $74.00M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, ATRA or OKYO?
OKYO returned -30.54% over the past 12 months, compared with -40.05% for ATRA (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.